Skip to main content

Table 1 Phase 3 trials of adjuvant chemotherapy for colorectal cancer

From: Cost-minimization analysis of adjuvant chemotherapy regimens given to patients with colorectal cancer in Japan

Trials

Race

Regimens

Primary endpoint

Result of the trials

Conclusion of the trials

Reference

16968

Whites

5-FU/LV vs. CapeOX

3-Year DFS rate

66.5 vs. 70.9 %

Superiority of CapeOX to 5-FU/LV

[8]

MOSAIC

Whites

LV5FU2 vs. FOLFOX4

3-Year DFS rate

65.3 vs. 72.2 %

Superiority of FOLFOX4 to LV5FU2

[9]

INT 0089

Whites

5-FU/LV (RPMI) vs. 5-FU/LV (Mayo)

5-Year OS rate

66.0 vs. 66.0 %

Non-inferiority of 5-FU/LV (RPMI) to 5-FU/LV (Mayo)

[20]

GERCOR C96.1

Whites

5-FU/LV (Mayo) vs. LV5FU2

6-Year DFS rate

65.0 vs. 66.0 %

Non-inferiority of 5-FU/LV (Mayo) to LV5FU2

[21]

Japanese

FOLFOX4 vs. mFOLFOX6

Response rate

53.7 vs. 46.6 %

Non-inferiority of mFOLFOX6 to FOLFOX4

[10]a

NSABP C-06

Whites

5-FU/LV vs. UFT/LV

5-Year OS rate

71.5 vs. 69.6 %

Non-inferiority of UFT/LV to 5-FU/LV

[12]

X-ACT

Whites

5-FU/LV vs. capecitabine

3-Year DFS rate

60.6 vs. 64.2 %

Non-inferiority of capecitabine to 5-FU/LV

[13]

ACTS-CC

Japanese

UFT/LV vs. S-1

3-Year DFS rate

72.5 vs. 75.5 %

Non-inferiority of S-1 to UFT/LV

[14]

  1. RPMI Roswell Park Memorial Institute regimen
  2. aPhase 2 trial